Publications

HER2 testing: evolution and update for a companion diagnostic assay.Robbins CJ, Bates KM, Rimm DL. Nat Rev Clin Oncol. 2025 Apr 7; 2025 Apr 7. PMID: 40195456.
Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.Bhatia A, Mehra R, Bauman J, Khan SA, Wei W, Neumeister V, Sandoval-Schaefer T, Alpaugh RK, Lango M, Rimm DL, Ridge JA, Burtness B. Head Neck. 2025 Apr 1; 2025 Apr 1. PMID: 40166973.
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, Boyaci C, Boman C, Poncet C, Ignatiadis M, Bai Y, Rimm DL, Cameron D, Bonnefoi H, Bergh J, MacGrogan G, Foukakis T. NPJ Breast Cancer. 2025 Mar 7; 2025 Mar 7. PMID: 40055382.
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.Trontzas IP, He M, Wurtz A, Robbins CJ, Robinson N, Bates K, Liu M, Aung TN, Scott L, Chan N, Burela S, Schillo J, Liebler DC, Hill S, Morrison RD, Vathiotis I, Syrigos KN, Goldberg SB, Politi K, Rimm DL. Clin Cancer Res. 2025 Mar 6; 2025 Mar 6. PMID: 40047548.
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach.Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Nat Rev Clin Oncol. 2025 Mar; 2025 Jan 16. PMID: 39820025.
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing.Taube JM, Sunshine JC, Angelo M, Akturk G, Eminizer M, Engle LL, Ferreira CS, Gnjatic S, Green B, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Jiménez-Sánchez D, Korski K, Lako A, Parra ER, Rebelatto MC, Rimm DL, Rodig SJ, Rodriguez-Canales J, Roskes JS, Schalper KA, Schenck E, Steele KE, Surace MJ, Szalay AS, Tetzlaff MT, Wistuba II, Yearley JH, Bifulco CB. J Immunother Cancer. 2025 Jan 8; 2025 Jan 8. PMID: 39779210.
The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably?Vidal JM, Tsiknakis N, Staaf J, Bosch A, Ehinger A, Nimeus E, Salgado R, Bai Y, Rimm DL, Hartman J, Acs B. EClinicalMedicine. 2024 Dec; 2024 Nov 15. PMID: 39634035.
Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay.Liu M, Vathiotis I, Robbins CJ, Chan NNN, Moutafi M, Burela S, Xirou V, Schalper KA, Herbst RS, Syrigos K, Rimm DL. Mod Pathol. 2024 Sep; 2024 Jul 2. PMID: 38964502.
BCAM (basal cell adhesion molecule) protein expression in different tumor populations.Burela S, He M, Trontzas IP, Gavrielatou N, Schalper KA, Langermann S, Flies DB, Rimm DL, Aung TN. Discov Oncol. 2024 Aug 29; 2024 Aug 29. PMID: 39207605.
Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma.Aung TN, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis I, Yaghoobi V, Kluger HM, Gerstein M, Rimm DL. Clin Cancer Res. 2024 Aug 15. PMID: 38837895.
High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC).Moutafi MK, Bates KM, Aung TN, Milian RG, Xirou V, Vathiotis IA, Gavrielatou N, Angelakis A, Schalper KA, Salichos L, Rimm DL. J Immunother Cancer. 2024 Jun 10; 2024 Jun 10. PMID: 38857914.
An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.Xirou V, Moutafi M, Bai Y, Nwe Aung T, Burela S, Liu M, Kimple RJ, Shabbir Ahmed F, Schultz B, Flieder D, Connolly DC, Psyrri A, Burtness B, Rimm DL. Oral Oncol. 2024 May; 2024 Mar 27. PMID: 38547779.
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.Gavrielatou N, Fortis E, Spathis A, Anastasiou M, Economopoulou P, Foukas GRP, Lelegiannis IM, Rusakiewicz S, Vathiotis I, Aung TN, Tissot S, Kastrinou A, Kotsantis I, Vagia EM, Panayiotides I, Rimm DL, Coukos G, Homicsko K, Foukas P, Psyrri A. Ann Oncol. 2024 Apr; 2023 Dec 28. PMID: 38159908.
Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.Su DG, Schoenfeld DA, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm DL, Khan SA, Halaban R, Kluger HM, Olino K, Galan A, Clune J. J Immunother Cancer. 2024 Mar 21; 2024 Mar 21. PMID: 38519058.
High-Plex Assessment of Biomarkers in Tumors.Aung TN, Bates KM, Rimm DL. Mod Pathol. 2024 Mar; 2024 Jan 12. PMID: 38219953.
Correlation of HER2 Protein Level With mRNA Level Quantified by RNAscope in Breast Cancer.Li X, Lee JH, Gao Y, Zhang J, Bates KM, Rimm DL, Zhang H, Smith GH, Lawson D, Meisel J, Chang J, Huo L. Mod Pathol. 2024 Feb; 2023 Dec 20. PMID: 38135153.
Automated scoring of tumor-infiltrating lymphocytes informs risk of death from thin melanoma: A nested case-case study.Tan SX, Aung TN, Claeson M, Acs B, Zhou C, Brown S, Lambie D, Baade PD, Pandeya N, Soyer HP, Smithers BM, Whiteman DC, Rimm DL, Khosrotehrani K. J Am Acad Dermatol. 2024 Jan; 2023 Sep 19. PMID: 37730017.
Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review.Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert PF, Harari PM, Rimm DL, Burtness B, Grasic Kuhar C, Carchman EH. Viruses. 2023 Nov 25; 2023 Nov 25. PMID: 38140561.
Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond.Lozar T, Laklouk I, Golfinos AE, Gavrielatou N, Xu J, Flynn C, Keske A, Yu M, Bruce JY, Wang W, Grasic Kuhar C, Bailey HH, Harari PM, Dinh HQ, Rimm DL, Hu R, Lambert PF, Fitzpatrick MB. Cancers (Basel). 2023 Oct 9; 2023 Oct 9. PMID: 37835599.
Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.Martinez-Morilla S, Moutafi M, Fernandez AI, Jessel S, Divakar P, Wong PF, Garcia-Milian R, Schalper KA, Kluger HM, Rimm DL. Oncoimmunology. 2023; 2023 Sep 27. PMID: 37781235.
Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores.Robbins CJ, Fernandez AI, Rimm DL. JAMA Oncol. 2023 Sep 1. PMID: 37498606.
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, Cai WL, Melnick MA, Robles-Oteiza C, Hinkley MM, Tsai JA, Hartley AV, Wei J, Wurtz A, Li F, Toki MI, Rimm DL, Homer R, Wilen CB, Xiao AZ, Qi J, Yan Q, Nguyen DX, Jänne PA, Kadoch C, Politi KA. Cancer Cell. 2023 Aug 14; 2023 Aug 3. PMID: 37541244.
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.Moutafi M, Koliou GA, Papaxoinis G, Economopoulou P, Kotsantis I, Gkotzamanidou M, Anastasiou M, Pectasides D, Kyrodimos E, Delides A, Giotakis E, Papadimitriou NG, Panayiotides IG, Perisanidis C, Fernandez AI, Xirou V, Poulios C, Gagari E, Yaghoobi V, Gavrielatou N, Shafi S, Aung TN, Kougioumtzopoulou A, Kouloulias V, Palialexis K, Gkolfinopoulos S, Strati A, Lianidou E, Fountzilas G, Rimm DL, Foukas PG, Psyrri A. Cancer Res Commun. 2023 Aug; 2023 Aug 10. PMID: 37575280.
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.Schoenfeld DA, Moutafi M, Martinez S, Djureinovic D, Merkin RD, Adeniran A, Braun DA, Signoretti S, Choueiri TK, Parisi F, Hurwitz M, Rimm DL, Wei W, Jilaveanu L, Kluger HM. J Immunother Cancer. 2023 Aug. PMID: 37586773.
Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.Horowitch B, Lee DY, Ding M, Martinez-Morilla S, Aung TN, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm DL, Ishizuka JJ. Clin Cancer Res. 2023 Aug 1. PMID: 37233452.
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.Chatziioannou E, Roßner J, Aung TN, Rimm DL, Niessner H, Keim U, Serna-Higuita LM, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop OT, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. EBioMedicine. 2023 Jul; 2023 Jun 7. PMID: 37295047.
Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists.Harms PW, Frankel TL, Moutafi M, Rao A, Rimm DL, Taube JM, Thomas D, Chan MP, Pantanowitz L. Mod Pathol. 2023 Jul; 2023 Apr 25. PMID: 37105494.
Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test.Fernandez AI, Gaule P, Rimm DL. Mod Pathol. 2023 Jul; 2023 Mar 15. PMID: 36925070.
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.Barrera C, Corredor G, Viswanathan VS, Ding R, Toro P, Fu P, Buzzy C, Lu C, Velu P, Zens P, Berezowska S, Belete M, Balli D, Chang H, Baxi V, Syrigos K, Rimm DL, Velcheti V, Schalper K, Romero E, Madabhushi A. NPJ Precis Oncol. 2023 Jun 1; 2023 Jun 1. PMID: 37264091.
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial.Fanucci KA, Bai Y, Pelekanou V, Nahleh ZA, Shafi S, Burela S, Barlow WE, Sharma P, Thompson AM, Godwin AK, Rimm DL, Hortobagyi GN, Liu Y, Wang L, Wei W, Pusztai L, Blenman KRM. NPJ Breast Cancer. 2023 May 13; 2023 May 13. PMID: 37179362.
Assessment of the Impact of Alternative Fixatives on HER2 Detection in Breast Cancer and Gastric Cancer Tumor Specimens.Feng W, Inoue R, Kuwata T, Niikura N, Fujii S, Kumaki N, Honda K, Xu LA, Goetz A, Gaule P, Cogswell J, Rimm DL, McGee R. Appl Immunohistochem Mol Morphol. 2023 May-Jun 01; 2023 Apr 24. PMID: 37093713.
Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.Fernandez AI, Robbins CJ, Gaule P, Agostini-Vulaj D, Anders RA, Bellizzi AM, Chen W, Chen ZE, Gopal P, Zhao L, Lisovsky M, Liu X, Shia J, Wang H, Yang Z, McCann L, Chan YG, Weidler J, Bates M, Zhang X, Rimm DL. Mod Pathol. 2023 May; 2023 Feb 13. PMID: 36889057.
Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma.Gavrielatou N, Vathiotis I, Aung TN, Shafi S, Burela S, Fernandez AI, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm DL. Cancer Res Commun. 2023 Apr; 2023 Apr 11. PMID: 37057033.
Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non-small Cell Lung Cancer.Aung TN, Gavrielatou N, Vathiotis IA, Fernandez AI, Shafi S, Yaghoobi V, Burela S, MacNeil T, Ahmed FS, Myint H, Flies DB, Langermann S, Rimm DL. Cancer Res Commun. 2023 Mar; 2023 Mar 21. PMID: 36960400.
Spatial characterization and quantification of CD40 expression across cancer types.Bates KM, Vathiotis I, MacNeil T, Ahmed FS, Aung TN, Katlinskaya Y, Bhattacharya S, Psyrri A, Yea S, Parkes A, Sadraei NH, Roychoudhury S, Rimm DL, Gavrielatou N. BMC Cancer. 2023 Mar 9; 2023 Mar 9. PMID: 36894898.
Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.Robbins CJ, Fernandez AI, Han G, Wong S, Harigopal M, Podoll M, Singh K, Ly A, Kuba MG, Wen H, Sanders MA, Brock J, Wei S, Fadare O, Hanley K, Jorns J, Snir OL, Yoon E, Rabe K, Soong TR, Reisenbichler ES, Rimm DL. Mod Pathol. 2023 Jan. PMID: 36788069.
The Pathologists' Conundrum.Rimm DL, Dacic S, Schnitt SJ. Arch Pathol Lab Med. 2023 Jan 1. PMID: 36577091.
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy.Rimm DL. JAMA Oncol. 2023 Jan 1. PMID: 36394848.
Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade.Vathiotis IA, Salichos L, Martinez-Morilla S, Gavrielatou N, Aung TN, Shafi S, Wong PF, Jessel S, Kluger HM, Syrigos KN, Warren S, Gerstein M, Rimm DL. NPJ Precis Oncol. 2022 Dec 15; 2022 Dec 15. PMID: 36522538.
Ki67 as a Companion Diagnostic: Good or Bad News?Dowsett M, Nielsen TO, Rimm DL, Hayes DF. J Clin Oncol. 2022 Nov 20; 2022 Jul 11. PMID: 35816627.
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. JCO Precis Oncol. 2022 Nov. PMID: 36446042.
Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.Schoenfeld DA, Merkin RD, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm DL, Kluger HM. Front Oncol. 2022; 2022 Oct 13. PMID: 36313654.
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai Y, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Buikema H, Chang MC, Dietz RL, Dodson A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hartman J, Kos Z, Lænkholm AV, Laurinavicius A, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Salgado R, Sugie T, van der Vegt B, Viale G, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL. Mod Pathol. 2022 Oct; 2022 Jun 21. PMID: 35729220.
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.Moutafi M, Robbins CJ, Yaghoobi V, Fernandez AI, Martinez-Morilla S, Xirou V, Bai Y, Song Y, Gaule P, Krueger J, Bloom K, Hill S, Liebler DC, Fulton R, Rimm DL. Lab Invest. 2022 Oct; 2022 May 20. PMID: 35595825.
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Lab Invest. 2022 Oct; 2022 May 17. PMID: 35581307.
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clin Cancer Res. 2022 Sep 1. PMID: 35903931.
Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC.Fernandez AI, Gavrielatou N, McCann L, Shafi S, Moutafi MK, Martinez-Morilla S, Vathiotis IA, Aung TN, Yaghoobi V, Bai Y, Chan YG, Weidler J, Herbst R, Bates M, Rimm DL. J Thorac Oncol. 2022 Sep; 2022 Jun 25. PMID: 35764237.
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. J Immunother Cancer. 2022 Aug. PMID: 36002182.
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms.Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL. EBioMedicine. 2022 Aug; 2022 Jul 7. PMID: 35810563.
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst RS, Schalper KA, Rimm DL. J Thorac Oncol. 2022 Aug; 2022 Apr 28. PMID: 35490853.
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer.Marczyk M, Qing T, O'Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. NPJ Breast Cancer. 2022 Jul 22; 2022 Jul 22. PMID: 35869114.
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer.Henick BS, Villarroel-Espindola F, Datar I, Sanmamed MF, Yu J, Desai S, Li A, Aguirre-Ducler A, Syrigos K, Rimm DL, Chen L, Herbst RS, Schalper KA. J Immunother Cancer. 2022 Jul. PMID: 35793873.
Development of an immunohistochemical assay for Siglec-15.Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL. Lab Invest. 2022 Jul; 2022 Apr 22. PMID: 35459795.
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Clin Cancer Res. 2022 Jun 13. PMID: 35377948.
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome.Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, Velu P, Leo P, Beig N, Li H, Toro P, Berezowska S, Baxi V, Balli D, Belete M, Rimm DL, Velcheti V, Schalper K, Madabhushi A. NPJ Precis Oncol. 2022 Jun 3; 2022 Jun 3. PMID: 35661148.
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.Lopez de Rodas M, Nagineni V, Ravi A, Datar IJ, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm DL, Herbst RS, Madabhushi A, Riess JW, Velcheti V, Hellmann MD, Gainor J, Schalper KA. J Immunother Cancer. 2022 Jun. PMID: 35649657.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. J Immunother Cancer. 2022 May. PMID: 35640927.
Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies.Han G, Schell MJ, Reisenbichler ES, Guo B, Rimm DL. Stat Med. 2022 Apr 15; 2021 Dec 12. PMID: 34897773.
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. JAMA Oncol. 2022 Apr 1. PMID: 35113160.
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.Dieli-Conwright CM, Harrigan M, Cartmel B, Chagpar A, Bai Y, Li FY, Rimm DL, Pusztai L, Lu L, Sanft T, Irwin ML. NPJ Breast Cancer. 2022 Mar 7; 2022 Mar 7. PMID: 35256599.
Standardization of PD-L1 immunohistochemistry.Martinez-Morilla S, Moutafi M, Rimm DL. Mod Pathol. 2022 Mar; 2021 Sep 10. PMID: 34508229.
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. NPJ Breast Cancer. 2022 Feb 3; 2022 Feb 3. PMID: 35115541.
CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression.Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. Sci Transl Med. 2022 Feb 2; 2022 Feb 2. PMID: 35108062.
Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.Gavrielatou N, Liu Y, Vathiotis I, Zugazagoitia J, Aung TN, Shafi S, Fernandez A, Schalper K, Psyrri A, Rimm DL. Clin Cancer Res. 2022 Jan 15; 2021 Oct 22. PMID: 34686497.
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV. Cancer Med. 2022 Jan; 2021 Dec 17. PMID: 34921525.
Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer.Farahmand S, Fernandez AI, Ahmed FS, Rimm DL, Chuang JH, Reisenbichler E, Zarringhalam K. Mod Pathol. 2022 Jan; 2021 Sep 7. PMID: 34493825.
Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.Yaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O'Meara T, Fernandez AI, Pusztai L, Rimm DL. Breast Cancer Res. 2021 Dec 14; 2021 Dec 14. PMID: 34906209.
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S. NPJ Breast Cancer. 2021 Dec 1; 2021 Dec 1. PMID: 34853355.
Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.Doroshow DB, Wei W, Gupta S, Zugazagoitia J, Robbins C, Adamson B, Rimm DL. J Thorac Oncol. 2021 Dec; 2021 Aug 26. PMID: 34455068.
PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both.Gavrielatou N, Shafi S, Gaule P, Rimm DL. J Natl Cancer Inst. 2021 Nov 29. PMID: 34097056.
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study.Zerdes I, Simonetti M, Matikas A, Harbers L, Acs B, Boyaci C, Zhang N, Salgkamis D, Agartz S, Moreno-Ruiz P, Bai Y, Rimm DL, Hartman J, Mezheyeuski A, Bergh J, Crosetto N, Foukakis T. NPJ Breast Cancer. 2021 Nov 19; 2021 Nov 19. PMID: 34799582.
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Clin Cancer Res. 2021 Nov 15; 2021 Aug 31. PMID: 34465600.
Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer.MacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, Driscoll K, Rimm DL. Cancers (Basel). 2021 Nov 2; 2021 Nov 2. PMID: 34771664.
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Neuro Oncol. 2021 Nov 2. PMID: 33914067.
An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.Bai Y, Cole K, Martinez-Morilla S, Ahmed FS, Zugazagoitia J, Staaf J, Bosch A, Ehinger A, Nimeus E, Hartman J, Acs B, Rimm DL. Clin Cancer Res. 2021 Oct 15; 2021 Jun 4. PMID: 34088723.
Measuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at Yale.Morrow JS, Gershkovich P, Gibson J, Gilshannon M, Kowalski D, Levi AW, Nguyen DX, Rimm DL, Xu ML, Sinard J. Acad Pathol. 2021 Jan-Dec; 2021 Oct 7. PMID: 34646939.
High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis.Li P, Yuan J, Ahmed FS, McHenry A, Fu K, Yu G, Cheng H, Xu ML, Rimm DL, Pan Z. Front Oncol. 2021; 2021 Aug 30. PMID: 34527580.
Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.Apostolidi M, Vathiotis IA, Muthusamy V, Gaule P, Gassaway BM, Rimm DL, Rinehart J. Cancer Res. 2021 Aug 15; 2021 Jun 21. PMID: 34185676.
Putting the Microenvironment into the Immunotherapy Companion Diagnostic.Moutafi M, Rimm DL. Clin Cancer Res. 2021 Jul 15; 2021 May 13. PMID: 33986024.
Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.Taube JM, Roman K, Engle EL, Wang C, Ballesteros-Merino C, Jensen SM, McGuire J, Jiang M, Coltharp C, Remeniuk B, Wistuba I, Locke D, Parra ER, Fox BA, Rimm DL, Hoyt C. J Immunother Cancer. 2021 Jul. PMID: 34266881.
A new tool for technical standardization of the Ki67 immunohistochemical assay.Aung TN, Acs B, Warrell J, Bai Y, Gaule P, Martinez-Morilla S, Vathiotis I, Shafi S, Moutafi M, Gerstein M, Freiberg B, Fulton R, Rimm DL. Mod Pathol. 2021 Jul; 2021 Feb 3. PMID: 33536573.
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. J Natl Cancer Inst. 2021 Jul 1. PMID: 33369635.
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.Berry S, Giraldo NA, Green BF, Cottrell TR, Stein JE, Engle EL, Xu H, Ogurtsova A, Roberts C, Wang D, Nguyen P, Zhu Q, Soto-Diaz S, Loyola J, Sander IB, Wong PF, Jessel S, Doyle J, Signer D, Wilton R, Roskes JS, Eminizer M, Park S, Sunshine JC, Jaffee EM, Baras A, De Marzo AM, Topalian SL, Kluger H, Cope L, Lipson EJ, Danilova L, Anders RA, Rimm DL, Pardoll DM, Szalay AS, Taube JM. Science. 2021 Jun 11. PMID: 34112666.
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. Nat Rev Clin Oncol. 2021 Jun; 2021 Feb 12. PMID: 33580222.
Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality.Vathiotis IA, Yang Z, Reeves J, Toki M, Aung TN, Wong PF, Kluger H, Syrigos KN, Warren S, Rimm DL. NPJ Precis Oncol. 2021 May 28; 2021 May 28. PMID: 34050252.
Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer.Datar IJ, Hauc SC, Desai S, Gianino N, Henick B, Liu Y, Syrigos K, Rimm DL, Kavathas P, Ferrone S, Schalper KA. Clin Cancer Res. 2021 May 15; 2021 Feb 18. PMID: 33602682.
STING enhances cell death through regulation of reactive oxygen species and DNA damage.Hayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, Leach K, Iyer R, Challa S, Sandoval-Schaefer T, Burtness BA, Rimm DL, Contessa JN. Nat Commun. 2021 Apr 19; 2021 Apr 19. PMID: 33875663.
Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer.Moutafi MK, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross JS, Syrigos K, Wei W, Pusztai L, Rimm DL, Vathiotis IA. J Immunother Cancer. 2021 Apr. PMID: 33833050.
Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry.Martinez-Morilla S, Villarroel-Espindola F, Wong PF, Toki MI, Aung TN, Pelekanou V, Bourke-Martin B, Schalper KA, Kluger HM, Rimm DL. Clin Cancer Res. 2021 Apr 1; 2021 Jan 27. PMID: 33504554.
Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer.Vathiotis IA, MacNeil T, Zugazagoitia J, Syrigos KN, Aung TN, Gruver AM, Vaillancourt P, Hughes I, Hinton S, Driscoll K, Rimm DL. Cancers (Basel). 2021 Mar 1; 2021 Mar 1. PMID: 33804482.
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. NPJ Breast Cancer. 2021 Feb 8; 2021 Feb 8. PMID: 33558513.
Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma.Moore MR, Friesner ID, Rizk EM, Fullerton BT, Mondal M, Trager MH, Mendelson K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H, Taback B, Geskin LJ, Horst B, Gardner K, Niedt G, Celebi JT, Gartrell-Corrado RD, Messina J, Ferringer T, Rimm DL, Saltz J, Wang J, Vanguri R, Saenger YM. Sci Rep. 2021 Feb 2; 2021 Feb 2. PMID: 33531581.
Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.Yeung J, Yaghoobi V, Aung TN, Vesely MD, Zhang T, Gaule P, Gunel M, Rimm DL, Chen L. J Neuropathol Exp Neurol. 2021 Jan 20. PMID: 33393633.
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.Vassilakopoulou M, Won M, Curran WJ, Souhami L, Prados MD, Langer CJ, Rimm DL, Hanna JA, Neumeister VM, Melian E, Diaz AZ, Atkins JN, Komarnicky LT, Schultz CJ, Howard SP, Zhang P, Dicker AP, Knisely JPS. Oncology. 2021; 2021 May 6. PMID: 33957633.
Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma.Johannet P, Coudray N, Donnelly DM, Jour G, Illa-Bochaca I, Xia Y, Johnson DB, Wheless L, Patrinely JR, Nomikou S, Rimm DL, Pavlick AC, Weber JS, Zhong J, Tsirigos A, Osman I. Clin Cancer Res. 2021 Jan 1; 2020 Nov 18. PMID: 33208341.
Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Oncoimmunology. 2020 Dec 29; 2020 Dec 29. PMID: 33457084.
Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry.MacNeil T, Vathiotis IA, Martinez-Morilla S, Yaghoobi V, Zugazagoitia J, Liu Y, Rimm DL. Biotechniques. 2020 Dec; 2020 Aug 27. PMID: 32852223.
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. J Immunother Cancer. 2020 Nov. PMID: 33239417.
PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.Ahmed FS, Gaule P, McGuire J, Patel K, Blenman K, Pusztai L, Rimm DL. Clin Cancer Res. 2020 Oct 15; 2020 Jul 24. PMID: 32709714.
Digital quantitative assessment of PD-L1 using digital spatial profiling.Gupta S, Zugazagoitia J, Martinez-Morilla S, Fuhrman K, Rimm DL. Lab Invest. 2020 Oct; 2020 Apr 6. PMID: 32249818.